MedTrace Logo

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

NCT05453825 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-01-31

No results posted yet for this study

Summary

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts:

* Cohort A: CRC
* Cohort B: Gastric and GEJ cancer
* Cohort C: TNBC
* Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

Conditions

Interventions

BIOLOGICAL

navicixizumab+paclitaxel

navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly

BIOLOGICAL

navicixizumab+irinotecan

navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W

BIOLOGICAL

navicixizumab monotherapy

navicixizumab 3 mg/kg Q2W

Sponsors & Collaborators

  • OncXerna Theraputics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2024-04-15
Completion
2024-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453825 on ClinicalTrials.gov